60505-3816 : Dasatinib 80 mg Oral Tablet, Film Coated


NDC: 60505-3816
Labeler: Apotex Corp.
Product Type: Human Prescription Drug
Drug Name:  Dasatinib
Dosage Form: Oral Tablet, Film Coated
Application #: ANDA203180
Rev. Date: 


NDC Package Codes:

  • 60505-3816-3: 30 TABLET, FILM COATED IN 1 BOTTLE (60505‑3816‑3)

Active Ingredients:

  • Dasatinib

Dosage Strength:

  • 80 mg

Pharmaceutical Classes:

  • Cytochrome P450 3A4 Inhibitors [MoA]
  • Kinase Inhibitor [EPC]
  • Protein Kinase Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 60505-3628 Dasatinib 20 mg Oral Tablet, Film Coated by Apotex Corp.
  • 60505-3629 Dasatinib 50 mg Oral Tablet, Film Coated by Apotex Corp.
  • 60505-3630 Dasatinib 70 mg Oral Tablet, Film Coated by Apotex Corp.
  • 60505-3631 Dasatinib 100 mg Oral Tablet, Film Coated by Apotex Corp.
  • 60505-3817 Dasatinib 140 mg Oral Tablet, Film Coated by Apotex Corp.
  • 66993-233 Dasatinib 20 mg Oral Tablet by Prasco Laboratories
  • 66993-234 Dasatinib 50 mg Oral Tablet by Prasco Laboratories
  • 66993-235 Dasatinib 70 mg Oral Tablet by Prasco Laboratories
  • 66993-236 Dasatinib 80 mg Oral Tablet by Prasco Laboratories
  • 66993-237 Dasatinib 100 mg Oral Tablet by Prasco Laboratories
  • 66993-238 Dasatinib 140 mg Oral Tablet by Prasco Laboratories

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 60505-3816 QR Code

< Prev: 60505-3810Next: 60505-3817 >

Related Discussions:

Time effect dasatinib
Could someone please tell me how long it will take before Dasatinib is out your system after stop using this medication?... 1 reply
dasatinib
new cml drup...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.